More on MDGL
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $439.34 |
|
|||
| Open | $431.65 | ||||
| 52 Wk High | $18.24 | ||||
| 52 Wk Low | $6.60 | ||||
| Day High | $439.43 | ||||
| Day Low | $421.88 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 476,025 | ||||
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
- H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
- Madrigal Pharmaceuticals (MDGL) PT Lowered to $529 at BofA Securities
- Truist Securities Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
- Madrigal Pharma (MDGL) Misses Q4 EPS by 197c
- Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
- Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
- Madrigal licenses six siRNA programs for MASH treatment development
Entities mentioned with MDGL
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Goldman Sachs | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Show More...
